
The randomized, double-blinded trial investigates the efficacy and safety of dexamethasone eye drops (1 mg/ml) in preventing the progression of retinopathy of prematurity (ROP) to Type 1 ROP in preterm infants. The study aims to reduce the need for laser or anti-VEGF treatment while monitoring adverse effects such as intraocular pressure and growth restriction. Follow-up will assess long-term visual outcomes in these infants, with results potentially influencing clinical guidelines for ROP management.
Like
Save
Share